DANSPOT: A Study of Population and Sex-specific Troponin Cutoffs for Ruling Out Acute Myocardial Infarction
Study Details
Study Description
Brief Summary
Acute myocardial infarction (MI) is defined as a rise and/or fall in cardiac troponins with at least one value above the 99th percentile upper reference limit (URL) in the context of symptoms or clinical evidence of myocardial ischemia. The URL is based on measurements in a healthy reference population. Currently, a sex-uniform manufacturer provided 99th percentile URL of troponin is utilized at Danish hospitals as a diagnostic cutoff for acute MI for both men and women. Reportedly, healthy men have twofold the troponin level compared to healthy women, suggesting that the use of a uniform URL for troponins may lead to the under-diagnostication of acute MI in women and potentially over-diagnostication in men.
The purpose of the DANSPOT study is to evaluate the clinical effect on diagnosis, treatment and outcomes in men and women presenting with acute MI of implementing international guidelines recommendations of sex-specific 99th percentile URLs for troponin into clinical practice.
First, to determine the sex-specific 99th percentile URLs of troponins based on a healthy Danish reference population, blood samples from Danish blood donors, were analyzed using one troponin T assay and four troponin I assays. Second, the DANSPOT study is a nationwide cluster-randomized trial with "stepped-wedge" design with participation of all 22 Danish hospital laboratories and associated departments of cardiology. With one-month intervals, each of 22 centers are randomized to shift from the presently applied uniform 99th percentile URL of troponin to our newly determined population and sex-specific 99th percentiles URLs. Each patient is followed in Danish registries for 12 months after first admission.
The hypothesis of the DANSPOT study is that implementation of population and sex-specific 99th URLs for troponin, will ensure that the right patients receive the right treatment. The investigators expect to detect significantly more women with acute MI, theoretically resulting in a more accurate diagnosis and treatment of women and men with acute MI.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The present use of non-sex specific diagnostic cut-off levels of troponins in the diagnosis of acute myocardial infarction (MI) leads to under-diagnostication of acute MI in women and over-diagnostication in men. The purpose of this study is to document this through a randomized nationwide clinical implementation of population and sex-specific cut-off levels.
Coronary artery disease (CAD) is globally the leading cause of mortality for men and women. The latest consensus statement defines myocardial infarction as 1) a rise and/or fall in cardiac troponins with 2) at least one value above the 99th percentile upper reference limit (URL) in the context of 3) symptoms or clinical evidence of myocardial ischemia. Thus, levels of cardiac troponins play a key role in the diagnostic work-up in general. Currently, uniform manufacturer-provided URLs, defined by the 99th percentile of cardiac troponins in a healthy reference population, is applied in Danish hospitals as a diagnostic cut-off for acute MI for both men and women.
Lower levels of cardiac troponins are seen in healthy women as compared to healthy men, i.e. twice as high levels are seen in men. On this basis the clinical use of one uniform 99th percentile URL for cardiac troponins - i.e. applying the same diagnostic levels for men and women - may lead to a systematic under-diagnostication of acute MI in women and potentially an over-diagnostication of acute MI in men. Accordingly, the use of sex-specific 99th percentile URL of cardiac troponins are now recommended in recent guidelines by international cardiological societies, but this remains to be introduced in clinical practice.
The 99th percentile URLs for cardiac troponins currently used in Danish Hospitals are provided by the manufacturer of each specific assay based on blood samples from a healthy reference population collected by the manufacturer. Studies have shown that the 99th percentile value is dependent on patient sex as well as on the reference population selected and the definition for "healthy" used in these studies. It is well known that the 99th percentile URL should stem from a local reference population. This recommendation has never been implemented in Denmark.
The overall purpose of the study is to evaluate the clinical effect of implementing population and sex-specific 99th percentile URL for cardiac troponins in Denmark.
To determine the sex-specific 99th percentile URLs of troponins based on a healthy Danish reference population, blood samples from healthy Danish blood donors, were analyzed using one troponin T assay and four troponin I assays. Second, the DANSPOT study is a nationwide cluster-randomized trial with "stepped-wedge" design with participation of all 22 Danish hospital laboratories and associated departments of cardiology. With one-month intervals, each of 22 centers are randomized to shift from the presently applied uniform 99th percentile URL of troponin to our newly determined population and sex-specific 99th percentiles URLs. Each patient is followed in Danish registries for 12 months after first admission.
The clinical significance of sex-specific 99th percentile URLs of troponin is poorly investigated and for the same reason not yet implemented in Denmark or many other countries. The basic hypothesis of the DANSPOT study is that the implementation of population and sex-specific 99th URLs for troponin, will ensure that the right patients receive the right treatment. The investigators expect to detect significantly more women with acute MI, theoretically resulting in a more accurate diagnosis and treatment of women and men with acute MI. This would be guideline-defining for implementing sex-specific cutoffs for cardiac troponin in Denmark as well as internationally as recommended in guidelines by professional cardiological societies.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: Control Arm - Current sex-uniform manufacturer provided 99th percentile URL of troponin Standard use of the current sex-uniform manufacturer provided 99th percentile URL of troponin is utilized at Danish hospitals as a diagnostic cutoff for acute MI for both men and women |
|
| Active Comparator: Intervention Arm - New population and sex-specific 99th percentile URLs of troponin Implementation of the new population and sex-specific 99th percentile URLs of troponin for the specific assay utilized at the enrolled centers. |
Diagnostic Test: Implementation of the new population and sex-specific 99th percentile URL for cardiac troponin
The new population and sex-specific 99th percentiles URLs will be implemented at all Danish hospitals receiving patients with chest pain for initial diagnostics for possible acute MI. This will take place as a randomized step-by-step introduction of population and sex-specific 99th percentile URLs for troponin in all hospital centers with a monthly start time interval. Each center is randomized to shifting from the sex-uniform manufacturer provided 99th percentile URL of cardiac troponin currently used nationwide to the new population and sex-specific 99th percentiles URLs provided by the DANSPOT study's first phase.
|
Outcome Measures
Primary Outcome Measures
- A composite of myocardial infarction, unplanned revascularisation (after index admission) or all cause mortality within 1 year of first admission for the primary cohort. [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Primary cohort is defined as the cohort of women and men with troponin levels between the newly determined population and sex-specific 99th percentile URLs for women and men and the uniform manufacturer provided 99th percentile URL.
Secondary Outcome Measures
- Number of women with coronary events in the primary cohort (after index admission) [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Primary cohort is defined as the cohort of women and men with troponin levels between the newly determined population and sex-specific 99th percentile URLs for women and men and the uniform manufacturer provided 99th percentile URL. Coronary events are defined as the prevalence of cardiovascular death, myocardial infarction or unplanned revascularisation (after index admission) within 1 year of first admission.
- Number of men with coronary events in the primary cohort (after index admission) [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Primary cohort is defined as the cohort of women and men with troponin levels between the newly determined population and sex-specific 99th percentile URLs for women and men and the uniform manufacturer provided 99th percentile URL. Coronary events are defined as the prevalence of cardiovascular death, myocardial infarction or unplanned revascularisation (after index admission) within 1 year of first admission.
- Number of women and men with coronary events in the primary cohort (after index admission) [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Primary cohort is defined as the cohort of women and men with troponin levels between the newly determined population and sex-specific 99th percentile URLs for women and men and the uniform manufacturer provided 99th percentile URL. Coronary events are defined as the prevalence of cardiovascular death, myocardial infarction or unplanned revascularisation (after index admission) within 1 year of first admission.
- Number of women diagnosed with acute MI (after index admission) [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
- Number of women diagnosed with acute MI [12 months from index admission]
Time frame starts from beginning of index admission, defined as first admission in the study period.
- Number of men diagnosed with acute MI (after index admission) [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
- Number of men diagnosed with acute MI [12 months from index admission]
Time frame starts from beginning of index admission, defined as first admission in the study period.
- The overall number of women and men diagnosed with acute MI (after index admission) [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
- The overall number of women and men diagnosed with acute MI [12 months from index admission]
Time frame starts from beginning of index admission, defined as first admission in the study period.
- Number of women receiving unplanned revascularization (after index admission) [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
- Number of women receiving revascularization [12 months from index admission]
Time frame starts from beginning of index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
- Number of men receiving unplanned revascularization (after index admission) [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
- Number of men receiving revascularization [12 months from index admission]
Time frame starts from beginning of index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
- The overall number of women and men receiving unplanned revascularization (after index admission) [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
- The overall number of women and men receiving revascularization [12 months from index admission]
Time frame starts from beginning of index admission, defined as first admission in the study period. Revascularization is defined as Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.
- Number of women with all cause death (after index admission) [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
- Number of women with all cause death [12 months from index admission]
Time frame starts from beginning of index admission, defined as first admission in the study period.
- Number of men with over-all death (after index admission) [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
- Number of men with over-all death [12 months from index admission]
Time frame starts from beginning of index admission, defined as first admission in the study period.
- The overall number of women and men with over-all death (after index admission) [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
- The overall number of women and men with over-all death [12 months from index admission]
Time frame starts from beginning of index admission, defined as first admission in the study period.
- Number of women receiving coronary angiographies or heart CT without revascularization [12 months from index admission]
Time frame starts from beginning of index admission, defined as first admission in the study period.
- Number of men receiving coronary angiographies or heart CT without revascularization [12 months from index admission]
Time frame starts from beginning of index admission, defined as first admission in the study period.
- The overall number of women and men receiving coronary angiographies or heart CT without revascularization [12 months from index admission]
Time frame starts from beginning of index admission, defined as first admission in the study period.
- Number of women receiving treatment with aspirin, dual anti-platelet therapy and/or statins [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
- Number of men receiving treatment with aspirin, dual anti-platelet therapy and/or statins [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
- The overall number of women and men receiving treatment with aspirin, dual anti-platelet therapy and/or statins [12 months after index admission]
Time frame starts at discharge from the hospital from the index admission, defined as first admission in the study period.
- Number of women re-admitted [12 months after index admission]
Readmission after index admission
- Number of men re-admitted [12 months after index admission]
Readmission after index admission
- The overall number of women and men re-admitted [12 months after index admission]
Readmission after index admission
- Length of hospital stay for women [30 days]
Calculated as days from date of index admission to date of discharge
- Length of hospital stay for men [30 days]
Calculated as days from date of index admission to date of discharge
- Length of hospital stay for women and men [30 days]
Calculated as days from date of index admission to date of discharge
Eligibility Criteria
Criteria
Inclusion Criteria:
- Suspicion of MI and a measurement of troponin
Exclusion Criteria:
- Age < 18 years
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital of Southern Jutland | Aabenraa | Denmark | 6200 | |
| 2 | Aalborg University Hospital | Aalborg | Denmark | 9000 | |
| 3 | Aarhus University Hospital | Aarhus | Denmark | 8000 | |
| 4 | Bispebjerg & Frederiksberg Hospital | Bispebjerg | Denmark | 2400 | |
| 5 | Rigshospitalet (Blegdamsvej) | Copenhagen Ø | Denmark | 2100 | |
| 6 | Sydvestjysk Sygehus | Esbjerg | Denmark | 6700 | |
| 7 | Glostrup University Hospital | Glostrup | Denmark | 2600 | |
| 8 | Gødstrup Regional Hospital | Gødstrup | Denmark | 7400 | |
| 9 | Herlev & Gentofte Hospital | Herlev | Denmark | 2730 | |
| 10 | C Torp-Pedersen | Hillerød | Denmark | 3400 | |
| 11 | North Denmark Regional Hospital | Hjørring | Denmark | 9800 | |
| 12 | Holbaek Sygehus | Holbæk | Denmark | 4300 | |
| 13 | Horsens Hospital | Horsens | Denmark | 8700 | |
| 14 | Amager & Hvidovre Hospital | Hvidovre | Denmark | 2650 | |
| 15 | Sygehus Lillebælt (Kolding Sygehus & Vejle Sygehus) | Kolding | Denmark | 6000 | |
| 16 | Zealand University Hospital | Køge | Denmark | 4600 | |
| 17 | Nykøbing Falster County Hospital | Nykøbing Falster | Denmark | 4800 | |
| 18 | Odense University Hospital | Odense | Denmark | 5000 | |
| 19 | Randers Regional Hospital | Randers | Denmark | 8930 | |
| 20 | Slagelse Sygehus | Slagelse | Denmark | 4200 | |
| 21 | Svendborg Hospital | Svendborg | Denmark | 5700 | |
| 22 | Central Jutland Regional Hospital (Viborg Hospital & Silkeborg Hospital) | Viborg | Denmark | 8800 |
Sponsors and Collaborators
- Herlev Hospital
- Rigshospitalet, Denmark
- Nordsjaellands Hospital
- Amager Hospital
- Bispebjerg Hospital
- Zealand University Hospital
- Slagelse Sygehus
- Nykøbing Falster County Hospital
- Holbaek Sygehus
- Odense University Hospital
- Svendborg Hospital
- Kolding Sygehus
- Aarhus University Hospital
- Gødstrup Regional Hospital
- Central Jutland Regional Hospital
- Randers Regional Hospital
- Glostrup University Hospital, Copenhagen
- Hvidovre University Hospital
- Vejle Hospital
- Hospital of Southern Jutland
- Horsens Hospital
- Aalborg University Hospital
- North Denmark Regional Hospital
- Sydvestjysk Sygehus
- Herlev and Gentofte Hospital
Investigators
- Principal Investigator: Kasper K Iversen, MD, DMsc, Herlev Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FSP 20067240